School Versus Community-based Albendazole Deworming For Control Of Soil Transmitted Helminths In School-age Children In The Philippines – A Cluster Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,336,408.00
Summary
Intestinal parasites are a global health problem. The World Health Organization recommends regular distribution of deworming drugs, targeting school aged children. This is effective for the children receiving the drugs but does not have an impact in the wider community. We aim to determine the best strategy for delivery of deworming drugs, to achieve the maximum benefit both for children and wider community, by directly comparing the benefits of a school-targeted vs a community-mass approach.
Increased Mortality Risk Following Osteoporotic Fractures: Data From Dubbo Epidemiology Study And A Consortium Of International Epidemiological Studies
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Osteoporotic fractures affect 1 in 2 women and 1 in 3 men over 60 and result in significant disability and premature mortality. Yet, less than 20% of those affected are treated. One of the reasons for this neglect is an uncertainty surrounding the fracture mortality association. This study will explore the magnitude and causes of this association and the effect of treatment on its prevention in a large multinational study. If positive, this evidence will boost osteoporosis treatment.
Disparities In Care And Outcome For People With Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$74,047.00
Summary
This thesis will investigate disparities in lung cancer care and outcomes, provide an overview of lung cancer disparities in NSW and seek to identify and assess an intervention to reduce lung cancer disparities. This will involve a systematic review of cancer disparity measures, empirical research to investigate patterns and predictors of disparity. Mixed methods will be used to investigate observed disparities and identify interventions to improve cancer care and outcomes in vulnerable groups.
Ending The Global Tuberculosis Epidemic: The Role Of Patient Costs
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
TB is an important public health problem worldwide. Rates of TB are declining but not fast enough to reach targets set by the World Health Organization to end the disease by 2035. One reason why TB remains an issue is the cost of health care for patients. My research will look at the costs of TB care for patients in Papua New Guinea and will compare costs between countries. I will look at policies to protect the sick and will conduct research to determine what works best in decreasing costs.
MULTICENTRE BRONCHIECTASIS STUDY: A Collaborative And International Study Of Bronchiectasis In Indigenous Children.
Funder
National Health and Medical Research Council
Funding Amount
$1,496,414.00
Summary
Aboriginal children have repeated pneumonia episodes; some get better while others develop bronchiectasis (a chronic lung disease). The risk factors associated with progression to bronchiectasis, and the natural history of bronchiectasis in this population is little known. Given the similarities of these diseases among indigenous populations of affluent countries and to increase study size, a collaborative and international study of Indigenous children (Aboriginal and Torres Strait Islander, New ....Aboriginal children have repeated pneumonia episodes; some get better while others develop bronchiectasis (a chronic lung disease). The risk factors associated with progression to bronchiectasis, and the natural history of bronchiectasis in this population is little known. Given the similarities of these diseases among indigenous populations of affluent countries and to increase study size, a collaborative and international study of Indigenous children (Aboriginal and Torres Strait Islander, New Zealand Maori or Pacific Islander and Alaskan Native) has been initiated. In Indigenous children, we aim to define the natural history of chronic moist cough (those at risk of developing bronchiectasis) and bronchiectasis, identify the risk factors associated with progression from early-mild disease (chronic moist cough) to bronchiectasis and to define the role of continuous antibiotic treatment in the prevention of recurrent pulmonary infections that are very common in these children. We plan to follow up Aboriginal children aged 12 months to 8 years diagnosed with bronchiectasis or chronic moist cough. For those diagnosed with bronchiectasis, after fully informed consent is obtained from the parent(s), the child will be allocated by chance to one of the 2 treatment regimes: (1) Azithromycin once-week or (2) placebo once-week. Children will receive the medication or the placebo for a period of 24 months. All these children will be clinically seen 2x-year by the study's paediatrician and 2x-year by the research nurse for the duration of the study. By documenting, for the first time, the epidemiology and natural history of children with chronic moist cough and bronchiectasis, the study will provide a much-needed rationale for their management. If we can scientifically show that this is true, that Azithromycin is effective in reducing the number of respiratory infections, this would be an achievable advance in the treatment in the field for these children.Read moreRead less